# A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT07493135** · EARLY_PHASE1 · RECRUITING · sponsor: **Suzhou Immunofoco Biotechnology Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** IMV102 treatment

## Key facts

- **NCT ID:** NCT07493135
- **Lead sponsor:** Suzhou Immunofoco Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493135, "A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07493135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*